SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study.

Document Type

Article

Publication Date

11-2025

Publication Title

Journal of Diabetes Research

Abstract

AIMS: The aim of this study is to evaluate the real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1RA) in patients with newly diagnosed Type 2 diabetes (T2DM), particularly among those with high cardiovascular risks or chronic kidney disease, and to identify demographic, clinical, and system-level factors associated with receiving these medications.

MATERIALS AND METHODS: This cross-sectional study analyzed electronic medical records (EMRs) of patients with newly diagnosed T2DM from 60 primary care clinics in West Michigan between April 2021 and January 2023. We assessed the documented prescription rates of SGLT2 inhibitors and GLP-1RAs within 3 months of diagnosis based on EMRs, particularly in high-risk subgroups.

RESULTS: Overall, 19.9% of

CONCLUSIONS: Despite guideline recommendations, SGLT2 inhibitors and GLP-1RAs are prescribed to only a minority of patients with newly diagnosed T2DM, even among those with clear indications. Efforts to improve guideline-adherent care in primary care settings are needed.

Volume

2025

First Page

6656982

Last Page

6656982

DOI

10.1155/jdr/6656982

ISSN

2314-6753

PubMed ID

41220901

Link to Full Text

Share

COinS